Savara Inc (NASDAQ:SVRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Savara Inc (NASDAQ:SVRA) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $9.86.

A number of analysts have weighed in on the stock. HC Wainwright decreased their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Wells Fargo & Company started coverage on shares of Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective for the company. Evercore ISI restated an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Thursday, December 19th.

Insider Activity

In other news, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joseph S. Mccracken purchased 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the transaction, the director now owns 210,837 shares in the company, valued at $621,969.15. This represents a 10.48 % increase in their position. The disclosure for this purchase can be found here. 5.13% of the stock is currently owned by company insiders.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently modified their holdings of SVRA. Virtu Financial LLC bought a new stake in shares of Savara in the 3rd quarter worth $67,000. BNP Paribas Financial Markets grew its stake in Savara by 258.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after purchasing an additional 18,534 shares during the period. Profund Advisors LLC purchased a new position in shares of Savara in the 2nd quarter worth about $105,000. China Universal Asset Management Co. Ltd. increased its holdings in Savara by 95.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 31,658 shares of the company’s stock worth $134,000 after buying an additional 15,423 shares during the last quarter. Finally, LMR Partners LLP grew its position in shares of Savara by 138.3% during the 3rd quarter. LMR Partners LLP now owns 36,800 shares of the company’s stock valued at $156,000 after acquiring an additional 132,900 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Trading Down 4.5 %

Shares of NASDAQ SVRA opened at $2.75 on Friday. The stock has a market cap of $471.95 million, a P/E ratio of -6.40 and a beta of 0.68. The firm has a 50 day moving average price of $3.17 and a two-hundred day moving average price of $3.80. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara has a 52-week low of $2.60 and a 52-week high of $5.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). As a group, equities analysts forecast that Savara will post -0.45 EPS for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.